Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Schott - Head of Development Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financial Officer Bettina Cockroft - Chief Medical Officer Mark McClung - Chief Operating Officer Conference Call Participants Gregory Harrison - Bank of America Yanan Zhu - Wells Fargo Harshita Polishetty - Barcl ...

Sangam Pioneering the Future of Genomic Medicines August 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, CAR-Treg and oth ...

Sangam Pioneering the Future of Genomic Medicines May 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-T ...

Sangam Pioneering the Future of Genomic Medicines May 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-T ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Rob Schott - Head of Development Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financial Officer Bettina Cockroft - Chief Medical Officer Conference Call Participants Yanan Zhu - Wells Fargo Nicole Germino - Truist Securities Luca Issi - RBC Capital Kelly O'Brien - Stifel Gregory Harrison - Ban ...

Sangam Pioneering the Future of Genomic Medicines February 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Aron Feingold - Head of Corporate Communications Sandy Macrae - CEO Mark McClung - COO Prathyusha Duraibabu - CFO Jason Fontenot - Chief Scientific Officer Rob Schott - Head of Development Bettina Cockroft - Chief Medical Officer Conference Call Participants Nicole Germino - Truist Securities Yanan Zhu - Wells Fargo Maury Raycroft - Jefferies Luca Issi - RBC Capital Aspen Mori - Bank o ...

Sangam Pioneering the Future of Genomic Medicines February 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, ...

Sangam Pioneering the Future of Genomic Medicines January 2022 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, C ...

Sang Corporate Presentation November 2021 Forward-Looking Statements This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to the potential to develop, obtain regulatory approvals for and commercialize safe and effective therapies to treat certain diseases and the timing, availability and costs of such therapies, the potential to use ZFP, ZFP-TF, ZFN, ZFP-Epi, CAR-Treg and other technologies ...